Headache in systemic mastocytosis: A case report with pathophysiological considerations

Cephalalgia

Volumn 25, Issue 4, 2005, Pages 314-316

  Ashina, Sait ^a   Ashina, M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CIMETIDINE; CITALOPRAM; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CELL HYPERPLASIA; DISEASE COURSE; EDEMA; FEMALE; FINGER JOINT; HEADACHE; HOSPITAL ADMISSION; HUMAN; MAST CELL; MIGRAINE WITHOUT AURA; PATHOPHYSIOLOGY; SIDE EFFECT; SKIN BIOPSY; SKIN MANIFESTATION; SYSTEMIC MASTOCYTOSIS; TENSION HEADACHE; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; URTICARIA PIGMENTOSA;

FEMALE; HEADACHE; HUMANS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX;

EID: 15944427118     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00852.x     Document Type: Article

References (27)

1. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419-32.
2. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002; 127:147-52.
3. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997; 349:1379-85.
4. Kumar S, Moody P. Mastocytosis. Pediatr Rev 2001; 22:33-4.
5. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92:10560-4.
6. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12:312-4.
7. Assaf C, Geilen CC, Tebbe B, Schulze K, Orfanos CE. Cutaneous mastocytosis. Lancet 2002; 359:1465.
8. Brockow K, Metcalfe DD. Mastocytosis. Curr Opin Allergy Clin Immunol 2001; 1:449-54.
9. Scully RE, Mark EJ, McNeely WF, Ebeling SH, Phillips LD. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-1992. A 57-year-old man with a 20-year history of episodic headache, flushing, hypotension, and occasional syncope. N Engl J Med 1992; 326:472-81.
10. Russell MB, Rasmussen BK, Brennum J, Iversen HK, Jensen RA, Olesen J. Presentation of a new instrument: the diagnostic headache diary. Cephalalgia 1992; 12:369-74.
11. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004; 24 Suppl 1:1-160.
12. Williams A, Krishna T, Frew A. Systemic mastocytosis. Lancet 2002; 360:1611.
13. Kaye WA, Passero MA. Respiratory distress and hypoxemia in systemic mastocytosis. Chest 1979; 75:87-8.
14. Donnan GA, Jarrott BJ. Urticaria pigmentosa-change in conscious state associated with rise in plasma histamine levels. Clin Exp Neurol 1979; 16:191-5.
15. Kirshenbaum AS, Kettelhut BV, Metcalfe DD, Garriga MM. Mastocytosis in infants and children: recognition of patterns of skin disease. Allergy Proc 1989; 10:17-21.
16. Burklow SL, Marney SR Jr. Mastocytosis: one year's experience. South Med J 1987; 80:51-4.
17. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122:695-717.
18. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The role of histamine in durai vessel dilation. Brain Res 2002; 956:96-102.
19. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997; 17:166-74.
20. Heatley RV, Denburg JA, Bayer N, Bienenstock J. Increased plasma histamine levels in migraine patients. Clin Allergy 1982; 12:145-9.
21. Haimart M, Pradalier A, Launay JM, Dreux C, Dry J. Whole blood and plasma histamine in common migraine. Cephalalgia 1987; 7:39-42.
22. Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain 1980; 8:253-9.
23. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995; 6:1475-9.
24. Bouchelouche K, Nordling J, Hald T, Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001; 166:1734-7.
25. LaMancusa R, Pulcinelli FM, Ferroni P, Lenti L, Manzari G, Pauri F, et al. Blood leukotrienes in headache: correlation with platelet activity. Headache 1991; 31:409-14.
26. Sheftell F, Rapoport A, Weeks R, Walker B, Gammerman I, Baskin S. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000; 40:158-63.
27. de Souza CD, Fragoso YD, Coelho FM, Pereira MM. Asthma plus migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antagonist. Headache 2002; 42:1044-7.